About Eleni Efstathiou
Dr. Efsathiou earned both MD and PhD degrees at the University of Athens and is currently a medical oncology fellow at MD Anderson Cancer Center.
New experimental medications that shut off androgen (the fuel for prostate cancer) synthesis will likely become a standard of care for advanced prostate cancer in the next few years. The goal of Dr. Efstathiou’s program is to measure androgen levels in the area of prostate cancer bone metastases to determine if androgens are undetectable, as is the case in tumor tissue from other sites, when total androgen suppressive medications are administered. It is thought that these studies will help determine which patients could benefit from or be resistant to these new medications.
Christopher Logothetis, MD will provide mentorship. Dr. Logothetis is a prostate cancer medical oncologist and heads the David H. Koch Prostate Cancer Center at MD Anderson. Dr. Logothetis has a long record of developing the careers of young investigators who have gone on to make important contributions to the field.
The 2008 Gen-Probe Incorporated – PCF Young Investigator Award
Eleni Efstathiou, MD, PhD
The University of Texas MD Anderson Cancer Center – Houston, TX